SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 426
Posts 23,077
Boards Moderated 4
Alias Born 09/11/06
160x600 placeholder
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) "PR Newswire (US)" - 12/8/2017 7:05:00 PM
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annu... "PR Newswire (US)" - 12/8/2017 7:30:00 AM
Detailed Research: Economic Perspectives on TiVo, Eli Lilly, Rigel Pharmaceuticals, SpartanNash, Nustar GP, and Hornbeck Offs... "GlobeNewswire Inc." - 12/4/2017 8:30:00 AM
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) "PR Newswire (US)" - 11/17/2017 4:05:00 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 11/7/2017 5:22:45 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/7/2017 4:09:39 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/7/2017 4:07:55 PM
Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update "PR Newswire (US)" - 11/7/2017 4:01:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2017 4:02:48 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/2/2017 7:32:47 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 11/2/2017 7:18:42 PM
Rigel Welcomes Gregg Lapointe to Board of Directors "PR Newswire (US)" - 11/2/2017 7:30:00 AM
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results "PR Newswire (US)" - 10/31/2017 7:30:00 AM
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares "PR Newswire (US)" - 10/10/2017 4:01:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/5/2017 5:31:45 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 5:23:13 PM
Rigel Announces Pricing Of Public Offering Of Common Stock "PR Newswire (US)" - 10/4/2017 10:36:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/3/2017 4:11:42 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/3/2017 4:08:40 PM
Rigel Announces Proposed Public Offering Of Common Stock "PR Newswire (US)" - 10/3/2017 4:01:00 PM
Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study "PR Newswire (US)" - 10/3/2017 7:30:00 AM
Rigel Provides Update on FDA Review of Fostamatinib for ITP "PR Newswire (US)" - 10/2/2017 7:30:00 AM
Rigel to Present at Cantor Fitzgerald Global Healthcare Conference "PR Newswire (US)" - 9/19/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2017 5:00:39 PM
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors "PR Newswire (US)" - 8/25/2017 7:30:00 AM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 430 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.



surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist